0001178913-25-002883 | 6-K | XBRL Viewer

Label	Element	Value
Changes In Right Of Use Asset And Lease Liabilities	blrx_ChangesInRightOfUseAssetAndLeaseLiabilities	$ 58,000
Changes In Right Of Use Asset And Lease Liabilities	blrx_ChangesInRightOfUseAssetAndLeaseLiabilities	$ 45,000
American Depositary Shares Sold	blrx_AmericanDepositarySharesSold	683,592
American Depositary Shares Sold	blrx_AmericanDepositarySharesSold	736,338
Warrants	blrx_Warrants	$ 1,691,000
Warrants	blrx_Warrants	4,360,000
Warrants	blrx_Warrants	1,691,000
Warrants	blrx_Warrants	$ 4,360,000
Shares Issued Registered Direct Offerings	blrx_SharesIssuedRegisteredDirectOfferings	103,037
Shares Issued Registered Direct Offerings	blrx_SharesIssuedRegisteredDirectOfferings	308,749
Shares Issued Registered Direct Offerings	blrx_SharesIssuedRegisteredDirectOfferings	858,303
Shares Issued Registered Direct Offerings	blrx_SharesIssuedRegisteredDirectOfferings	391,697
Issuances Of Warrants Measured	blrx_IssuancesOfWarrantsMeasured	$ 10,465,000
Profit Loss From Non Operating Activities	blrx_ProfitLossFromNonOperatingActivities	7,807,000
Profit Loss From Non Operating Activities	blrx_ProfitLossFromNonOperatingActivities	(1,851,000)
Profit Loss From Non Operating Activities	blrx_ProfitLossFromNonOperatingActivities	12,297,000
Profit Loss From Non Operating Activities	blrx_ProfitLossFromNonOperatingActivities	5,793,000
Warrant Issuance Costs	blrx_WarrantIssuanceCosts	207,000
Warrant Issuance Costs	blrx_WarrantIssuanceCosts	$ 0
Exercise Price Of Share Issued	blrx_ExercisePriceOfShareIssued	$ 21.86
Exercise Price Of Share Issued	blrx_ExercisePriceOfShareIssued	21.85
Exercise Price Of Share Issued	blrx_ExercisePriceOfShareIssued	8
Exercise Price Of Share Issued	blrx_ExercisePriceOfShareIssued	$ 7.996
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	$ 8,058,000
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	(5,876,000)
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	(2,182,000)
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	0
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	0
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	0
Increase Decrease Though Pre Funded Warrants Exercised	blrx_IncreaseDecreaseThoughPreFundedWarrantsExercised	$ 0
Warrants issued to purchase shares	blrx_WarrantsIssuedToPurchaseShares	205,893
Warrants issued to purchase shares	blrx_WarrantsIssuedToPurchaseShares	1,250,000
Warrants issued to purchase shares	blrx_WarrantsIssuedToPurchaseShares	62,500
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	$ 0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	(66,000)
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	(66,000)
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	646,000
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	(646,000)
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Increase Decrease Through Expired Of Options	blrx_IncreaseDecreaseThroughExpiredOfOptions	0
Gross Proceeds From Issuing Shares	blrx_GrossProceedsFromIssuingShares	4,700,000
Gross Proceeds From Issuing Shares	blrx_GrossProceedsFromIssuingShares	$ 8,900,000
Warrants expiration period	blrx_WarrantsExpirationPeriod	four years
Warrants expiration period	blrx_WarrantsExpirationPeriod	five years
Warrants expiration period	blrx_WarrantsExpirationPeriod	five years
Issuance Cost Of Warrants	blrx_IssuanceCostOfWarrants	$ 642,000
Issuance Cost Of Warrants	blrx_IssuanceCostOfWarrants	$ 702,000
Exercise price of warrants	blrx_ExercisePriceOfWarrants	$ 23.6
Exercise price of warrants	blrx_ExercisePriceOfWarrants	8
Exercise price of warrants	blrx_ExercisePriceOfWarrants	$ 10
COMMITMENTS AND CONTINGENT LIABILITIES	blrx_CommitmentsAndContingentLiabilities
COMMITMENTS AND CONTINGENT LIABILITIES	blrx_CommitmentsAndContingentLiabilities
Day One Loss On Warrants Measured	blrx_DayOneLossOnWarrantsMeasured	$ (1,383,000)
Beneficially Own In Excess	blrx_BeneficiallyOwnInExcess	4.99%
Beneficially Own In Excess	blrx_BeneficiallyOwnInExcess	4.99%
Interest And Exchange Differences On Short Term Deposits	blrx_InterestAndExchangeDifferencesOnShortTermDeposits	$ 201,000
Interest And Exchange Differences On Short Term Deposits	blrx_InterestAndExchangeDifferencesOnShortTermDeposits	48,000
Recognition Of Day One Loss Within Profit Or Loss Warrants Measured	blrx_RecognitionOfDayOneLossWithinProfitOrLossWarrantsMeasured	163,000
Changes In Fair Value Through Profit Or Loss Warrants Measured	blrx_ChangesInFairValueThroughProfitOrLossWarrantsMeasured	(6,573,000)
Aggregate offering price	blrx_AggregateOfferingPrice	25,000,000
Aggregate offering price	blrx_AggregateOfferingPrice	9,000,000
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	3,056,000
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	(3,056,000)
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	0
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	0
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	0
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	0
Issuance Of Share Capital And Warrants, Net	blrx_IssuanceOfShareCapitalAndWarrantsNet	0
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	25,664,000
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	(20,988,000)
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	501,000
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	0
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	0
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	0
Issuance Of Share Capital Pre Funded Warrants And Warrants Net	blrx_IssuanceOfShareCapitalPreFundedWarrantsAndWarrantsNet	5,177,000
Warrants Reserve	blrx_WarrantsReserve	5,367,000
Warrants Reserve	blrx_WarrantsReserve	$ 3,686,000
Percentage of commission on sales agreement	blrx_PercentageOfCommissionOnSalesAgreement	3.00%
Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables	blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables	$ 359,000
Adjustments For Decrease Increase In Prepaid Expenses And Other Operating Receivables	blrx_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndOtherOperatingReceivables	(1,146,000)
Total Change In Operating Asset And Liability	blrx_TotalChangeInOperatingAssetAndLiability	(17,974,000)
Total Change In Operating Asset And Liability	blrx_TotalChangeInOperatingAssetAndLiability	$ 1,357,000
Authorized Share Capital Value	blrx_AuthorizedShareCapitalValue	$ 500,000,000
Authorized Share Capital Value	blrx_AuthorizedShareCapitalValue	2,000,000,000
Issued And Paid Up Share Capital Value	blrx_IssuedAndPaidUpShareCapitalValue	133,667,057
Issued And Paid Up Share Capital Value	blrx_IssuedAndPaidUpShareCapitalValue	$ 255,761,119
Issued And Paid Up Share Capital Value	blrx_IssuedAndPaidUpShareCapitalValue	$ 38,096,940
Issued And Paid Up Share Capital Value	blrx_IssuedAndPaidUpShareCapitalValue	71,819,083
Interest on loans	blrx_InterestOnLoans	1,997,000
Interest on loans	blrx_InterestOnLoans	0
Exchange differences on lease liability	blrx_ExchangeDifferencesOnLeaseLiability	189,000
Exchange differences on lease liability	blrx_ExchangeDifferencesOnLeaseLiability	110,000
Changes In Fair Value Recorded As A Non-operating Income	blrx_ChangesInFairValueRecordedAsANonoperatingIncome	(165,000)
Changes In Fair Value Recorded As A Non-operating Income	blrx_ChangesInFairValueRecordedAsANonoperatingIncome	441,000
Changes In Fair Value Recorded As A Non-operating Income	blrx_ChangesInFairValueRecordedAsANonoperatingIncome	(1,500,000)
Changes In Fair Value Recorded As A Non-operating Income	blrx_ChangesInFairValueRecordedAsANonoperatingIncome	5,500,000
Total Income And Expense Not Involving Cash Flows	blrx_TotalIncomeAndExpenseNotInvolvingCashFlows	(7,252,000)
Total Income And Expense Not Involving Cash Flows	blrx_TotalIncomeAndExpenseNotInvolvingCashFlows	(5,312,000)
Maturities Of Short Term Deposits	blrx_MaturitiesOfShortTermDeposits	(28,660,000)
Maturities Of Short Term Deposits	blrx_MaturitiesOfShortTermDeposits	(12,926,000)
Warrant Offering Consideration	blrx_WarrantOfferingConsideration	500,000
Lawsuit Claim Amount	blrx_LawsuitClaimAmount	6,500,000
Lawsuit Claim Amount	blrx_LawsuitClaimAmount	7,200,000
Proceeds From Warrant Issue	blrx_ProceedsFromWarrantIssue	8,900,000
Proceeds From Exercise Warrants	blrx_ProceedsFromExerciseWarrants	10,000,000
Amount allocated to warrant	blrx_AmountAllocatedToWarrant	27,000
Amount allocated to warrant	blrx_AmountAllocatedToWarrant	700,000
Fair Value Of Ordinary Warrants Adjusted Amount	blrx_FairValueOfOrdinaryWarrantsAdjustedAmount	1,400,000
Proceeds From Exercise Of Warrants After Deducting Fees And Expenses	blrx_ProceedsFromExerciseOfWarrantsAfterDeductingFeesAndExpenses	8,900,000
Supplemental information on interest received in cash	blrx_SupplementalInformationOnInterestReceivedInCash	931,000
Supplemental information on interest received in cash	blrx_SupplementalInformationOnInterestReceivedInCash	583,000
Supplemental information on interest paid in cash	blrx_SupplementalInformationOnInterestPaidInCash	971,000
Supplemental information on interest paid in cash	blrx_SupplementalInformationOnInterestPaidInCash	$ 694,000

FINANCINGS

6 Months Ended

Jun. 30, 2025

Disclosure Of Equity Financing [Abstract]

FINANCINGS

NOTE 6 – FINANCINGS

Securities purchase agreement – Highbridge

In November 2024, the Company completed a registered direct offering to certain funds associated with Highbridge Capital Management LLC (“Highbridge”) of 103,037 ADSs and 308,749 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $21.86 and $21.85, respectively. The Company also issued to the investors unregistered ordinary warrants to purchase an aggregate of 205,893 ADSs. Gross proceeds from the offering totaled $9.0 million, with net proceeds of $8.9 million, after deducting fees and expenses.

The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire four years from the date of issuance, and have an exercise price of $23.60 per ADS.

A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the outstanding share capital of the Company immediately after giving effect to such exercise.

The ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.

The pre-funded warrants have been classified in shareholders’ equity, with initial recognition at fair value on the date issued, using the same assumptions as the ordinary warrants.

The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.19%, and an average standard deviation of 84.5%. The gross consideration initially allocated to ordinary warrants amounted to $2,721,000, with total issuance costs initially allocated to the ordinary warrants amounting to $27,000.

The fair value of the ordinary warrants amounted to $304,000 as of June 30, 2025, and was based on the then current price of an ADS, a risk-free interest rate of 3.7%, an average standard deviation of 96.0%, and on the remaining contractual life of the ordinary warrants.

The changes in fair value for the three and six months ended June 30, 2025 of $(165,000) and $441,000, respectively, have been recorded as non-operating income (expenses) in the statement of comprehensive loss.

During the six months ended June 30, 2025, 101,357 of the pre-funded warrants were exercised, and none of the ordinary warrants were exercised.

January 2025 offering

In January 2025, the Company completed a registered direct offering to certain institutional investors of 858,303 ADSs and 391,697 pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $8.00 and $7.996, respectively. The Company also issued to investors in the offering unregistered ordinary warrants to purchase an aggregate of 1,250,000 ADSs. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004 per ADS. The ordinary warrants are exercisable immediately, expire five years from the date of issuance, and have an exercise price of $8.00 per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder) of the outstanding share capital of the Company immediately after giving effect to such exercise.

In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase 62,500 ADSs. These warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $10.00 per ADS. The offering consideration allocated to the placement agent warrants amounted to $0.5 million.

Gross proceeds from the offering totaled $10.0 million, with net proceeds of $8.9 million, after deducting fees and expenses.

The investors’ ordinary warrants have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance date and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.

The pre-funded warrants have been classified in shareholders’ equity. The fair value of the ordinary warrants is computed using the Black-Scholes option pricing model and is determined by using a level 3 valuation technique. The fair value of the ordinary warrants upon issuance was computed based on the then-current price of an ADS, a risk-free interest rate of 4.41%, and an average standard deviation of 90.2%. The fair value initially allocated to the investor ordinary warrants amounted to $10.4 million, with total issuance costs initially allocated to the ordinary warrants amounting to $0.7 million.

Due to a difference between the fair value at initial recognition and the transaction price (“Day 1 loss”), upon initial recognition, the fair value of the ordinary warrants was adjusted by the amount of $1.4 million, to reflect the unrecognized day 1 loss. Following initial recognition, the unrecognized day 1 loss of the warrants is being amortized over its contractual life.

The fair value of the ordinary warrants amounted to $3.6 million as of June 30, 2025, and was based on the then current price of an ADS, a risk-free interest rate of 3.79%, an average standard deviation of 93.0%, and on the remaining contractual life of the warrants. The changes in fair value for the three months and six months ended June 30, 2025, amounting to $(1,500,000) and $5,500,000, respectively, have been recorded as a non-operating income (expenses) in the statement of comprehensive loss.

As of June 30, 2025, all of the pre-funded warrants had been exercised, and none of the ordinary warrants had been exercised.

In accordance with IFRS 2, the placement agent warrants have been classified in shareholders’ equity, with initial recognition at fair value on the date issued, using the same assumptions as the investor warrants.

AT-THE-MARKET ("ATM") SALES AGREEMENT WITH HCW	6 Months Ended
AT-THE-MARKET ("ATM") SALES AGREEMENT WITH HCW	Jun. 30, 2025
Disclosure Of Issuances Of Share Capital [Abstract]
AT-THE-MARKET (“ATM”) SALES AGREEMENT WITH HCW	NOTE 4 – AT-THE-MARKET (“ATM”) SALES AGREEMENT WITH HCW The Company maintains an ATM facility with H.C. Wainwright & Co., LLC (“HCW”) pursuant to an ATM sales agreement entered into in September 2021. In accordance with the agreement, the Company is entitled, at its sole discretion, to offer and sell through HCW, acting as a sales agent, ADSs having an aggregate offering price of up to $25.0 million throughout the period during which the ATM facility remains in effect. The Company has agreed to pay HCW a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. During the six months ended June 30, 2025, 683,592 ADSs were issued for total net proceeds of $4.7 million. From the effective date of the agreement through the issuance date of this report, 736,338 ADSs have been sold under the program for total net proceeds of $8.9 million.

SUPPLEMENTAL FINANCIAL INFORMATION (Schedule of Cost of revenues) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Disclosure of supplementary financial statement information [Abstract]
Cost related to license revenues	$ 72	$ 330	$ 106	$ 1,071
Cost of product sales	$ 0	$ 85	$ 0	$ 153

Print Document
Reports AT-THE-MARKET ("ATM") SALES AGREEMENT WITH HCW FINANCINGS SUPPLEMENTAL FINANCIAL INFORMATION Accounting Policies MATERIAL ACCOUNTING POLICIES (Policies) Tables SUPPLEMENTAL FINANCIAL INFORMATION (Tables) Details SUPPLEMENTAL FINANCIAL INFORMATION (Schedule of Cost of revenues) (Details) Uncategorized Uncategorized Items - zk2533581_htm.xml All Reports